Core Viewpoint - Ruizhi Pharmaceutical is transitioning from a "subcontracting" model to a "full-package" service model in the CRO industry, aiming to provide comprehensive solutions that span from drug development to commercialization, thereby enhancing efficiency and reducing risks for clients [2][3]. Group 1: Financial Performance - Ruizhi Pharmaceutical forecasts a net profit attributable to shareholders of between 12.3 million and 18.45 million yuan for the year 2025, marking a turnaround from a loss of 226 million yuan in the previous year [1]. Group 2: Industry Challenges and Opportunities - The CRO industry is undergoing a fundamental shift, with clients now seeking strategic partners that can systematically reduce R&D risks and enhance overall efficiency, rather than merely executing tasks [2]. - Key opportunities in the industry include the acceleration of domestic innovative drug internationalization, the rise of new modalities such as ADCs and nucleic acid drugs, and the integration of new technologies like AI in drug development [2]. Group 3: Strategic Transformation - The company is committed to a strategic transformation towards a "CRO + CDMO" integrated service system, which aims to provide seamless connections across all stages of drug development, thereby reducing communication and technical adaptation costs for clients [3]. - Ruizhi Pharmaceutical is leveraging a dual approach of "full-package strategy + CVC ecosystem investment" to build a new growth foundation, enhancing its service capabilities and extending its technological depth [3]. Group 4: R&D Investment Focus - The company focuses its R&D investments on two main areas: the construction and upgrading of comprehensive R&D platforms, particularly for new modality drugs, and the integration of cutting-edge technologies to enhance R&D efficiency and reduce costs [5]. - Ruizhi Pharmaceutical has developed a comprehensive nucleic acid innovation platform and is actively exploring collaborations in organoid technology to further empower drug development [5]. Group 5: Competitive Advantages - The company's core competitive advantages include a robust R&D technology platform with over 20 years of experience, a comprehensive service capability from target validation to commercialization, and the ability to integrate disruptive innovations like AI and advanced manufacturing technologies [6]. - Ruizhi Pharmaceutical's global strategy includes establishing a presence in key markets such as North America and Europe, with 80% of its orders coming from these regions, while also focusing on domestic market growth through strategic partnerships [6]. Group 6: Future Vision - The company is developing a biopharmaceutical industrial park in Malaysia to serve Southeast Asia and expand its international business framework, aiming to facilitate the global reach of Chinese innovative drugs [7]. - Ruizhi Pharmaceutical envisions becoming a trusted partner in the global life sciences sector, continuing to innovate and deepen its integrated service offerings in the pharmaceutical R&D landscape [7].

Group 1: Company Strategy - The company's current strategic direction is driven by a "full-package strategy + CVC ecological investment" model, aiming to strengthen its full-chain service capabilities from PCC to IND to NDA while expanding service coverage and technical depth [2] - The company has participated in projects such as the Shenzhen Luohu Donghai Wisdom Pharmaceutical Industry Investment Fund, leveraging its "chain master" role to integrate industry resources and achieve win-win development [3] Group 2: Customer Structure - The customer base is diverse, including multinational pharmaceutical companies (MNCs), biotech firms, and research institutions, with mid-sized biotech companies and MNCs forming the core customer group [4] - These key customers are characterized by stable development, ample funding, and controllable project advancement, providing a solid foundation for the company's ongoing business growth [4] Group 3: AI Technology Integration - The company has over 20 years of R&D experience, utilizing AI technology to enhance research efficiency, shorten development cycles, and reduce the number of candidate compounds, thereby lowering overall R&D costs [4] - A systematic approach is being taken to build a "scientific research intelligent hub platform," improving efficiency in daily operations and applying AI in critical areas such as antibody discovery and drug property prediction [5] Group 4: Nucleic Acid Field Development - The company has established a comprehensive innovative platform covering large and small nucleic acids, with a complete technical system that includes chemical modifications and innovative monomers [6] - Collaborations with companies like Saint Nor Pharmaceutical and Haiyou Biology have been initiated to strengthen capabilities in the nucleic acid sector [7] Group 5: Performance Goals - The three-year stock incentive performance targets have a gradually increasing range due to the initial phase of strategic execution, focusing on overcoming current challenges and key tasks such as the CVC industry fund layout for 2024-2025 [7] - The strategic effects are expected to gradually manifest from 2026 to 2027, leading to an accelerated release cycle of full-package orders, hence the broader performance target range [7]